Insulet Corporation - Common Stock (PODD)

Based on a technical and fundamental analysis of NASDAQ:PODD we conclude: INSULET CORP (NASDAQ:PODD)—A High-Growth Stock Gearing Up for Its Next Upward Move.

Looking back on patient monitoring stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including iRhythm (NASDAQ:IRTC) and its peers.

Over the past six months, Insulet has been a great trade. While the S&P 500 was flat, the stock price has climbed by 14.6% to $265.87 per share. This was partly due to its solid quarterly results, and the performance may have investors wondering how to approach the situation.

Let’s dig into the relative performance of Insulet (NASDAQ:PODD) and its peers as we unravel the now-completed Q4 patient monitoring earnings season.

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how ResMed (NYSE:RMD) and the rest of the patient monitoring stocks fared in Q4.

Based on fundamental and technical analysis of NASDAQ:PODD we conclude: INSULET CORP (NASDAQ:PODD): a strong growth stock preparing for the next leg up?.

Based on Fundamental Analysis it can be said that NASDAQ:PODD is a growth stock which is not overvalued.

Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to becoming $100 billion corporations are ripe with competition, ranging from giants with vast resources to agile upstarts eager to disrupt the status quo.

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how patient monitoring stocks fared in Q4, starting with DexCom (NASDAQ:DXCM).

Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Tuesday.

Curious about the S&P500 stocks that are in motion on Tuesday? Join us as we explore the top movers within the S&P500 index during today's session.

Seeking insights into today's market movers? Discover the S&P500 gap up and gap down stocks in today's session on Tuesday. Stay informed about the latest market trends.

Medical tech company Masimo (NASDAQ:MASI) will be reporting earnings tomorrow after the bell. Here’s what to look for.

Medical device company Integra LifeSciences (NASDAQ:IART) will be announcing earnings results tomorrow before market hours. Here’s what to look for.

Discover the S&P500 stocks that are experiencing unusual trading volume in today's session. Find out more about these stocks below.

Curious about the S&P500 stocks that are showing activity before the opening bell on Friday?

Insulet's Q4 sales grew 17.2% to $597.5 million, exceeding forecasts. Omnipod revenue surged, and 2025 guidance projects up to 20% growth.

Insulin delivery company Insulet Corporation (NASDAQ:PODD) reported Q4 CY2024 results beating Wall Street’s revenue expectations, with sales up 17.2% year on year to $597.5 million. Guidance for next quarter’s revenue was better than expected at $545.5 million at the midpoint, 0.7% above analysts’ estimates. Its non-GAAP profit of $1.15 per share was 12.6% above analysts’ consensus estimates.

Insulin delivery company Insulet Corporation (NASDAQ:PODD) will be announcing earnings results tomorrow after market close. Here’s what to expect.